# A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving

> **NCT01684150** · PHASE1 · COMPLETED · sponsor: **Epizyme, Inc.** · enrollment: 51 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Myelodysplastic Syndrome
- Myeloproliferative Disorders

## Interventions

- **DRUG:** EPZ-5676

## Key facts

- **NCT ID:** NCT01684150
- **Lead sponsor:** Epizyme, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2015-11
- **Final completion:** 2016-02
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2024-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01684150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01684150, "A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01684150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*